Literature DB >> 28893518

Curative approaches for sickle cell disease: A review of allogeneic and autologous strategies.

Daniel E Bauer1, Christian Brendel2, Courtney D Fitzhugh3.   

Abstract

Despite sickle cell disease (SCD) first being reported >100years ago and molecularly characterized >50years ago, patients continue to experience severe morbidity and early mortality. Although there have been substantial clinical advances with immunizations, penicillin prophylaxis, hydroxyurea treatment, and transfusion therapy, the only cure that can be offered is hematopoietic stem cell transplantation (HSCT). In this work, we summarize the various allogeneic curative approaches reported to date and discuss open and upcoming clinical research protocols. Then we consider gene therapy and gene editing strategies that may enable cure based on autologous HSCs.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28893518     DOI: 10.1016/j.bcmd.2017.08.014

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  7 in total

1.  Health-Related Quality of Life and Personal Life Goals of Adults With Sickle Cell Disease After Hematopoietic Stem Cell Transplantation.

Authors:  Agatha M Gallo; Crystal Patil; Tokunbo Adeniyi; Lewis L Hsu; Damiano Rondelli; Santosh Saraf
Journal:  West J Nurs Res       Date:  2018-04-06       Impact factor: 1.967

2.  Fetal hemoglobin induction in sickle erythroid progenitors using a synthetic zinc finger DNA-binding domain.

Authors:  Biaoru Li; Xingguo Zhu; Mir A Hossain; Cameron R Guy; Hongyan Xu; Jörg Bungert; Betty S Pace
Journal:  Haematologica       Date:  2018-04-05       Impact factor: 9.941

3.  Simple chronic transfusion therapy, a crucial therapeutic option for sickle cell disease, improves but does not normalize blood rheology: What should be our goals for transfusion therapy?

Authors:  Jon A Detterich
Journal:  Clin Hemorheol Microcirc       Date:  2018       Impact factor: 2.375

4.  Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons.

Authors:  Angela Rivers; Kestis Vaitkus; Ramasamy Jagadeeswaran; Maria Armila Ruiz; Vinzon Ibanez; Filippo Ciceri; Fernando Cavalcanti; Robert E Molokie; Yogen Saunthararajah; James Douglas Engel; Joseph DeSimone; Donald Lavelle
Journal:  Exp Hematol       Date:  2018-08-17       Impact factor: 3.084

5.  In Vivo Outcome of Homology-Directed Repair at the HBB Gene in HSC Using Alternative Donor Template Delivery Methods.

Authors:  Sowmya Pattabhi; Samantha N Lotti; Mason P Berger; Swati Singh; Christopher T Lux; Kyle Jacoby; Calvin Lee; Olivier Negre; Andrew M Scharenberg; David J Rawlings
Journal:  Mol Ther Nucleic Acids       Date:  2019-06-07       Impact factor: 8.886

6.  Rational targeting of a NuRD subcomplex guided by comprehensive in situ mutagenesis.

Authors:  Falak Sher; Mir Hossain; Davide Seruggia; Vivien A C Schoonenberg; Qiuming Yao; Paolo Cifani; Laura M K Dassama; Mitchel A Cole; Chunyan Ren; Divya S Vinjamur; Claudio Macias-Trevino; Kevin Luk; Connor McGuckin; Patrick G Schupp; Matthew C Canver; Ryo Kurita; Yukio Nakamura; Yuko Fujiwara; Scot A Wolfe; Luca Pinello; Takahiro Maeda; Alex Kentsis; Stuart H Orkin; Daniel E Bauer
Journal:  Nat Genet       Date:  2019-06-28       Impact factor: 38.330

7.  Sideroblastic anaemia in a patient with sickle cell disease.

Authors:  Nikitha Vobugari; Mansi Chaturvedi; Ilana Miriam Schlam-Camhi; Hedy Patricia Smith
Journal:  BMJ Case Rep       Date:  2022-02-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.